RBD3133

Suzhou – October 7, 2026 -- Suzhou Ribo Life Science (06938.HK) and its Swedish subsidiary Ribocure Pharmaceuticals AB have submitted a Phase I Clinical Trial Application in the European Union for RBD3133, a small interfering RNA (siRNA) therapeutic targeting the INHBE gene for overweight and obesity.

RBD3133 silences a gene linked to healthier fat distribution in human genetic studies

RBD3133 is designed to selectively suppress INHBE, which encodes the protein activin E. Human genetic data show that individuals with naturally occurring loss-of-function variants in INHBE exhibit healthier fat distribution, improved metabolic profiles, and a lower estimated risk of coronary heart disease and type 2 diabetes.